(CercleFinance.com) – Advicenne rose by more than 4% on Friday on the Paris Stock Exchange after taking stock of its activities during the holding of its general meeting yesterday.
The pharmaceutical company specializing in kidney disease, which already markets four drugs, notably recalled having recorded “many successes” in recent months.
For the record, its main drug, Sibnayal, has received marketing authorization in Europe and the United Kingdom for the treatment of distal renal tubular acidosis (dRTA).
After signing the first distribution partnerships in Europe, the company now intends to expand sales over the coming months, not only in the five major European markets (Germany, United Kingdom, France, Spain and Italy) but also outside the continent.
Advicenne also says it wants to ensure ‘controlled’ clinical and regulatory development of ADV7103, a product which is currently undergoing an advanced phase of clinical development in the United States and Canada in dRTA and in cystinuria in Europe and in the USA.
It should be noted that the Board of Directors held after the meeting appointed Philippe Boucheron, a Bpifrance executive, as Chairman of the Board of Directors.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
